XSTO
INTEG B
Market cap45mUSD
Jun 11, Last price
21.85SEK
1D
5.74%
1Q
38.56%
IPO
7.43%
Name
Integrum AB
Chart & Performance
Profile
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | 2016‑04 | |
Income | |||||||||
Revenues | 104,119 40.19% | 74,272 33.29% | |||||||
Cost of revenue | 12,857 | 15,870 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 91,262 | 58,402 | |||||||
NOPBT Margin | 87.65% | 78.63% | |||||||
Operating Taxes | 2,004 | (5,342) | |||||||
Tax Rate | 2.20% | ||||||||
NOPAT | 89,258 | 63,744 | |||||||
Net income | 4,032 -124.92% | (16,182) -176.07% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 843 | 3,946 | |||||||
BB yield | -0.08% | -0.82% | |||||||
Debt | |||||||||
Debt current | 1,580 | 1,491 | |||||||
Long-term debt | 11,269 | 14,339 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (1) | ||||||||
Net debt | (4,052) | (34,556) | |||||||
Cash flow | |||||||||
Cash from operating activities | (12,744) | (25,098) | |||||||
CAPEX | (11,402) | ||||||||
Cash from investing activities | (11,627) | (11,402) | |||||||
Cash from financing activities | (649) | 3,077 | |||||||
FCF | 75,547 | 86,665 | |||||||
Balance | |||||||||
Cash | 16,901 | 41,921 | |||||||
Long term investments | 8,466 | ||||||||
Excess cash | 11,695 | 46,673 | |||||||
Stockholders' equity | (34,168) | 105,331 | |||||||
Invested Capital | 183,378 | 104,774 | |||||||
ROIC | 61.95% | 41.47% | |||||||
ROCE | 61.16% | 38.56% | |||||||
EV | |||||||||
Common stock shares outstanding | 19,279 | 18,322 | |||||||
Price | 57.20 118.74% | 26.15 -37.74% | |||||||
Market cap | 1,102,759 130.16% | 479,125 -37.22% | |||||||
EV | 1,098,707 | 594,774 | |||||||
EBITDA | 93,428 | 59,557 | |||||||
EV/EBITDA | 11.76 | 9.99 | |||||||
Interest | 560 | 10 | |||||||
Interest/NOPBT | 0.61% | 0.02% |